December 8, 2017 - By Michael Collier

The stock of BRIACELL THERAPEUTICS CORPORATION (OTCMKTS:BCTXF) registered a decrease of 66.67% in short interest. BCTXF’s total short interest was 11,000 shares in December as published by FINRA. Its down 66.67% from 33,000 shares, reported previously. With 12,700 shares average volume, it will take short sellers 1 days to cover their BCTXF’s short positions.

The stock decreased 8.16% or $0.0082 during the last trading session, reaching $0.0923. About shares traded. BriaCell Therapeutics Corp. (OTCMKTS:BCTXF) has 0.00% since December 8, 2016 and is . It has underperformed by 16.70% the S&P500.

BriaCell Therapeutics Corp., a biotechnology company, engages in the research and development of cancer immunotherapy technology in Canada. The company has market cap of $10.99 million. It is involved in developing BriaVax, a genetically engineered whole-cell vaccine that is in Phase I/IIa clinical trial to treat advanced breast cancer, as well as other cancers comprising prostate, ovarian, pancreas, lung, and bladder cancers; and BriaDx, a companion diagnostic test for BriaVax. It currently has negative earnings.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: